



# **HEALTHCARE COMMITTEE**



The AmCham China Healthcare Committee includes members from three major industry subsegments: 1) Pharmaceuticals, 2) Medical Devices, Equipment, and Diagnostics, and 3) Hospitals, Clinics, and Healthcare Services. The Healthcare Committee's 2022 strategic plan is grouped around three types of activities: Advocacy, Business, and Community (ABCs).

**Committee Priorities:** 

Advocacy-**High** 

Business-**Medium** (information sharing) Community-**Low** (networking)

# **MISSION**

To improve the policy environment in ways that benefit both the industry and members.

To share and discuss cross-sector business and policy issues to get smarter about the industry.

To strengthen closer communication and cooperation for healthcare between the US and China.

# MEMBER PROFILE

Among our 77 member companies, 60+ are in the Healthcare Committee.

In total, more than 200 individuals participate in the Healthcare Committee.

#### LEADERSHIP



Co-Chair: Roberta Lipson, United Family Healthcare



Co-Chair: Jeffrey Que, Johnson & Johnson China



Co-Chair: Alice Xu, Boston Scientific

#### MAIN ACTIVITIES

Healthcare Chapter (drafted by Committee members) in annual AmCham China White Paper.

White Paper Delivery Meeting with central government agencies -NHSA 国家医疗保障局,NMPA 国家药监局,NHC 卫健委.

Call for Comments helps members deliver their messages, suggestions, and feedback to central government for new policies and regulations.

Debriefing Events (Closed-door) – invite industry experts and officials to explain new policies and discuss topical issues with members.

Member Delegation Visits to provincial governments for direct exchange of ideas on specific issues.

Between 2016-2020, the Healthcare Committee submitted 21 advocacy letters to relevant government authorities, with significant progress


In 2017, the Healthcare Committee won the Chamber's President's Award for Advocacy.

In addition to the Healthcare Committee, AmCham China also oversees the **US-China Healthcare** Cooperation Program (HCP). Established in 2011 as a US-China Public Private Partnership on a healthcare framework during the Summit between US President Barack Obama and Chinese President Hu Jintao, the HCP is a collaborative initiative to build closer working relations between the two governments while leveraging healthcare industry strengths. Other aims include fostering long-term cooperation with China in the areas of public health, policy research, training, R&D, technology, and supporting the Chinese government's goal of enhancing patients' access to healthcare services in China.





# 2022 COMMITTEE STRATEGIC FOCUS



**Partnerships:** To grow Committee membership and deepen our advocacy impact, we hope to cooperate with major associations such as **RDPAC**, **PhRMA**, **AdvaMed**, and **APAC Med** where possible. We will also build relationships with member consulting firms with healthcare expertise (such as North Head and APCO Worldwide), as well as insurance, PE, and VC member firms focused on healthcare.

# **2022 WORKING PLAN**

SUB-SEGMENT	Q1	Q2	Q3	Q4
Pharmaceuticals	<ul> <li>Jan: Planning meeting followed by a Committee mixer</li> <li>Mixer open to non-healthcare Committee members interested in healthcare (e.g. insurance, VC/PE, tech and consulting companies)</li> <li>Feb-March: Finalize White Paper submission</li> </ul>	• June: White Paper Delivery Meeting to National Healthcare Security Administration (NHSA) 国家医疗保障局	August: Digital healthcare event via T&I Initiative – potential topics include tele-health, diagnostics using big data, digital transformation of distribution channels and more      Consider partnering with Plug & Play, Tencent, Web MD, Microsoft, or Intel	One provincial visit based on the interests and priorities of members
Devices, diagnostic, Equipment		• July: White Paper Delivery Meeting to National Medical Products Administration (NMPA) 国家药品监督管理局 or National Health Committee (NHC) 卫健委		One provincial visit based on the interests and priorities of members
Services		• <b>July:</b> Joint Event with HCP (Topic TBD)		



Xian Janssen Pharmaceutical



# **ACTIVE COMMITTEE MEMBERS**

Pharmaceutical	Devices, Equipment, and	Smiths Medical	
Abbott Laboratories	Diagnostics	Starkey China	
Abbvie Pharmaceutical	A.Menarini China	Stryker Healthcare Products	
Allergan	Abbott Medical Devices	Thermo Fisher Scientific	
Amgen	Agilent Technologies	Tianjin Amcare Women's &	
AstraZeneca	Alcon (China) Ophthalmic Product	Children's Hospital	
Bayer	Beckman Coulter Commercial Enterprise (China)	Tianjin Bonna-Agela Technologies	
CASI Pharmaceutical INC	Becton Dickinson Medical Devices	Varian Medical Systems	
Charles River	Bio-Rad Laboratories	Waters Corporation	
Gilead Sciences		Zimmer Medical Insurance	
Grifols	BSC International Medical Trading	Hospitals, Clinics, and Services	
GSK	Carl Zeiss	Arrail Dental Clinic	
Laboratoires Expansciece	Coherent	Beijing Arrail Dental Limited	
Mentholatum Pharmaceuticals	Coloplast	Beijing RDPAC Intl. Consulting	
Merck Serono*	Cordis Medical Devices	Beijing Saint Lucia Consulting	
	Edwards Lifesciences	Bearapy	
MSD Holding	Glaxo Smith Kline	Chindex International	
MSD R&D	Hologic	Dalian Anshen Clinic	
Novartis Group	Illumina Trading	Home Instead Senior Care	
Novozymes Investment  Pfizer Finance Share Service	Intuitive Surgical- Fosun Medical Technology	iKang Healthcare group	
(Dalian)	Invitrogen Trading	IME-Conrad Corp.	
Pfizer Investment	Johnson and Johnson	Irvine Scientific Consulting	
Pfizer Pharmaceuticals	Medtronic	(Shanghai)	
Roche Pharma	Merit Medical	Joinway Dental Clinic	
Sanofi China	PerkinElmer Management	United Family Hospitals	
Sanofi China Tianjin Branch	Pharnorcia	Veeva Software	
Sanofi China Wuhan Branch	Promega	Vitup Group	
Sino-American Tianjin SmithKline and French Lab	Rayco Asia Pacific Investment& Management		

RB (China)

**Roche Diagnostics**